TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9115004
Drug: 750 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 micrograms of vaginal misoprostol after 50 mg/m2 methotrexate IM
Study: 9115004
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms of vaginal misoprostol after 50 mg/m2 methotrexate IM
Study: 9115004
Drug: Vaginal route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal route for second dose of misoprostol after one dose failed
Study: 9115004
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route for second dose of misoprostol after one dose failed
Study: 9115004
Drug: 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 methotrexate
Study: 9115004
Drug: Three vaginal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three vaginal doses of misoprostol 8 hr apart starting on Day 5
Study: 9115004
Drug: One vaginal
Normalized name: estrone Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vaginal dose of misoprostol
Study: 8262821
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection leaving positive margins followed by postoperative adjuvant therapy (majority received postoperative radiotherapy +/- chemotherapy)
Study: 8262821
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection leaving positive margins followed by postoperative adjuvant therapy
Study: 3985390
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of 1.5% lidocaine with 80 mg methylprednisolone (group II)
Study: 3985390
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of preservative-free physiologic saline solution and 80 mg methylprednisolone (group I, control group)
Study: 28363320
Drug: opioid agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: opioid agonist treatment at the time of follow-up
Study: 28363320
Drug: no agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: no agonist treatment
Study: 25527035
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg doses, four times daily, total daily dose of 800 mg)
Study: 21368390
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carnitine and coenzyme Q10
Study: 19484178
Drug: Tumescent solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent solution containing lidocaine and epinephrine
Study: 19484178
Drug: Tumescent solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent solution containing only epinephrine
Study: 17208005
Drug: Modern antiemetic
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern antiemetic therapy
Study: 24859491
Drug: Imipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (150 mg/day)
Study: 2787399
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n = 53) with occlusal interferences eliminated annually
Study: 2787399
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 46) undergoing placebo treatment
Study: 23547047
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination of pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet)
Study: 21334736
Drug: Everolimus-based regimen
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus-based regimen (trough concentrations 6-10 ng/mL) with enteric-coated mycophenolate sodium (1440 mg/day) and corticosteroids
Study: 23229691
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravitreal triamcinolone acetonide
Study: 16978576
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravitreal triamcinolone acetonide
Study: 11708699
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of Nortesten (72 mg)
Study: 11708699
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of Nortesten (144 mg)
Study: 11708699
Drug: Nortesten (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortesten (both doses)
Study: 31619205
Drug: Combined NRT
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined NRT (nicotine patch & gum)
Study: 31619205
Drug: Single NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single NRT (nicotine patch)
Study: 28189292
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (32 IE)
Study: 22542215
Drug: Antibiotics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics with facilitated referral (AFR)
Study: 20571437
Drug: Ziprasidone (80‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (80‐160 mg/d given twice a day, mean modal dose of 112 mg/d)
Study: 20571437
Drug: Ziprasidone (80‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (80‐120 mg/d given every day, mean modal dose of 96 mg/d)
Study: 20571437
Drug: Haloperidol (5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5‐20 mg/d, mean modal dose of 12 mg/d)
Study: 17919155
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy (n = 21)
Study: 19902288
Drug: Preoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative and postoperative chemotherapy
Study: 12149204
Drug: Low-dose Methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Methotrexate (LDMTX: 6 oral doses of 30 mg/m(2)) plus intravenous Mercaptopurine (MP: 1 g/m(2))
Study: 12149204
Drug: High-dose Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Methotrexate (HDMTX: intravenous 1 g/m(2)) plus intravenous Mercaptopurine (MP: 1 g/m(2))
Study: 12149204
Drug: Mercaptopurine (MP:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mercaptopurine (MP: 1 g/m(2)) alone
Study: 12149204
Drug: High-dose Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Methotrexate plus Mercaptopurine (HDMTX + MP)
Study: 12149204
Drug: Low-dose Methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Methotrexate plus Mercaptopurine (LDMTX + MP)
Study: 7072708
Drug: Ibuprofen (IPF)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (IPF)
Study: 23771541
Drug: Adrenaline (1/200,000,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline (1/200,000, 5 ml) during nasal packing (Group A1)
Study: 23771541
Drug: Adrenaline (1/200,000,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline (1/200,000, 5 ml) during nasal packing with desflurane (Group A2)
Study: 23771541
Drug: Desflurane administration
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane administration (Group C)
Study: 21358314
Drug: gemfibrozil, niacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil, niacin and cholestyramine therapy
Study: 21358314
Drug: lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lifestyle intervention and pharmacologic therapy
Study: 19587364
Drug: Greater insulin
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater insulin secretion
Study: 19587364
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle modification (ILS) and metformin
Study: 19587364
Drug: Male sex
Normalized name: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Male sex and insulin sensitivity
Study: 8934214
Drug: Nitrendipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (5 mg bid)
Study: 6416701
Drug: 30 mg/30
Normalized name: Kapectolin, 5.8 g-130 mg/30 mL oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/30 ml Adriamycin
Study: 6416701
Drug: 20 mg/40
Normalized name: mitomycin 20 mg/40 mL (0.5 mg/mL) INTRAVESIC SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/40 ml Adriamycin
Study: 6416701
Drug: 20 mg/40
Normalized name: mitomycin 20 mg/40 mL (0.5 mg/mL) INTRAVESIC SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/40 ml mitomycin C
Study: 27379829
Drug: Daily combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily combination of vitamin D3 (1200 IU), folic acid (0.5 mg), vitamin B12 (0.5 mg), vitamin B6 (50 mg), and calcium carbonate (456 mg) (group A)
Study: 22217987
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg orally daily for 4 days, then 200 mg once weekly for 6 months
Study: 22217987
Drug: K-712, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-712, 1 tablet twice a day for 4 weeks and then for the first 2 weeks of each month for a total of 6 months
Study: 17323595
Drug: Sildenafil (phosphodiesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (phosphodiesterase type 5 inhibitor)
Study: 15206088
Drug: Ointment-based product
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment-based product
Study: 15206088
Drug: Aerosol spray
Normalized name: Betadine Aerosol Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol spray
Study: 11148806
Drug: Low-dose sequential
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sequential HRT
Study: 9102063
Drug: MFP-SR (76
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFP-SR (76 mg b.i.d.)
Study: 26650434
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (2.2 g protein/kg/day)
Study: 26650434
Drug: Standard-protein diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-protein diet (1.1 g protein/kg/day)
Study: 25899445
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg weekly dose of sirolimus (SIR)
Study: 23537892
Drug: Intravenous B-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous B-type natriuretic peptide (BNP)
Study: 12690275
Drug: GenHevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: GenHevac B vaccine (3 standard injections at 30-day intervals)
Study: 12690275
Drug: GenHevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: GenHevac B vaccine
Study: 12579420
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 15 ml/kg
Study: 12579420
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 5 ml/kg after volume resuscitation
Study: 12579420
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 10 ml/kg after volume resuscitation
Study: 12579420
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 15 ml/kg after volume resuscitation
Study: 1820897
Drug: 5‐ASA capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA capsule formulation
Study: 1820897
Drug: Single unit
Normalized name: LIDOCAINE 4 g TOPICAL PATCH [LIDOCORE (single unit patch)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single unit tablet of 5‐ASA
Study: 6349765
Drug: Bacille Calmette-Guérin
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacille Calmette-Guérin (BCG) maintenance therapy
Study: 6349765
Drug: Cyclophosphamide (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (orally administered)
Study: 26951205
Drug: Phenolic-rich olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenolic-rich olive leaf extract (OLE) 136 mg oleuropein; 6 mg hydroxytyrosol
Study: 26774673
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) supplementation (2 × 500 mg/day for four months)
Study: 15786549
Drug: 3-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day rabeprazole-based triple therapy (amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., rabeprazole 20 mg b.i.d.)
Study: 15786549
Drug: 7-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day rabeprazole-based triple therapy (amoxicillin 1000 mg b.i.d., clarithromycin 500 mg b.i.d., rabeprazole 20 mg b.i.d.)
Study: 15786549
Drug: 3-day rabeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day rabeprazole-based triple therapy
Study: 11932292
Drug: fenproporex 25
Normalized name: fenproporex 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenproporex 25 mg/d
Study: 11932292
Drug: sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sibutramine 10 mg/d
Study: 11932292
Drug: orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: orlistat 120 mg tid
Study: 9428449
Drug: Bicarbonate bath
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate bath of 40 mEq/L (experimental group)
Study: 9428449
Drug: Standard bicarbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bicarbonate bath of 35 mEq/L (control group)
Study: 8085374
Drug: SPf(66)n, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf(66)n, a chimeric molecule derived from Plasmodium falciparum proteins, details on dosage and duration not available
Study: 1008247
Drug: Modification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modification of infusion regimen (substituting glucose solution with distilled water and Ringer lactate with normal saline and 5 mval/l KCI)
Study: 30484833
Drug: Any oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any oral anticoagulant
Study: 26817808
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy and general discussions (Group C)
Study: 20194455
Drug: Nonbiologic DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonbiologic DMARD treatment after 12 weeks
Study: 20194455
Drug: Low response
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low response to treatment at 12 weeks
Study: 14668283
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid + Iron (60 mg)
Study: 14668283
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid + Iron + Zinc (30 mg)
Study: 11289091
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with morphine and ketorolac
Study: 9428033
Drug: Nucleus Mini
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus Mini 22 Cochlear Implant System with SPEAK coding strategy
Study: 9428033
Drug: Clarion Cochlear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarion Cochlear Implant System with CIS coding strategy (and one with CA coding strategy)
Study: 9428033
Drug: Nucleus Mini
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleus Mini 22 Cochlear Implant System
Study: 9428033
Drug: Clarion Cochlear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarion Cochlear Implant System
Study: 10133873
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition
Study: 2516090
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose administration (D5W)
Study: 30701617
Drug: Continuous moderate‐intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous moderate‐intensity exercise + prior carbohydrate intake (10 g per person)
Study: 26124907
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg OD for 12 weeks)
Study: 26124907
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg OD for 12 weeks)
Study: 26124907
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg OD) + Atorvastatin (10 mg OD for 12 weeks)
Study: 26124907
Drug: Control (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (No treatment)
Study: 23872701
Drug: Low-dose interoceptive
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose interoceptive exposure (IE) as prescribed in Panic Control Treatment
Study: 23872701
Drug: Low-dose interoceptive
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose interoceptive exposure (IE) without controlled breathing
Study: 19843741
Drug: Oral contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contrast media
Study: 19843741
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and IV contrast media
Study: 19843741
Drug: Simulated low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated low radiation dose
Study: 17402790
Drug: Bispecific antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific antibodies
Study: 17402790
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antibodies
Study: 17402790
Drug: VEGF or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF or VEGF receptor blockers
Study: 17402790
Drug: Heat shock
Normalized name: Human heat shock protein antigen 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat shock protein 90 inhibitors
Study: 17402790
Drug: Multi-targeted kinase
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-targeted kinase inhibitors (sunitinib, sortenib)
Study: 12888156
Drug: No anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anthracycline treatment
Study: 10579147
Drug: Celgene formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celgene formulations (two formulations)
Study: 10579147
Drug: Tortuga formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tortuga formulation
Study: 10579147
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three formulations
Study: 1680649
Drug: 19.2 mg
Normalized name: ALUMINUM SESQUICHLOROHYDRATE 19.2 mg in 100 g TOPICAL AEROSOL, SPRAY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19.2 mg oral dose of [14C]PV
Study: 1680649
Drug: 9.9 mg
Normalized name: benzocaine 9.9 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.9 mg iv dose of [14C]PV
Study: 1680649
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg nonradiolabeled oral dose of PV
Study: 6802413
Drug: Desferrioxamine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine (average weekly doses of more than 4 g)
Study: 31843024
Drug: Amiloride 10
Normalized name: amiloride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 10 mg/day
Study: 31843024
Drug: Amiloride 20
Normalized name: amiloride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 20 mg/day
Study: 25367904
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg every 12 hours
Study: 21707862
Drug: Pet therapy
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pet therapy intervention for 6 weeks
Study: 21707862
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pet therapy)
Study: 19779146
Drug: Serotonin and
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin and noradrenaline selective reuptake inhibitor (SNRI)
Study: 17005087
Drug: Simotang oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simotang oral liquid
Study: 10731485
Drug: Arbutamine infusion
Normalized name: ARBUTAMINE
DrugBank: Arbutamine (DB01102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arbutamine infusion
Study: 6241563
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g tiapride daily for 3 weeks
Study: 30857452
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy for fast ventricular arrhythmia (VA)
Study: 30857452
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy for slow VA
Study: 29356759
Drug: Modified primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified primary continuous prophylaxis started by 25 IU/kg once per week, increased to twice or 3 times a week according to defined bleeding events.
Study: 23848944
Drug: Internet-based problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based problem-solving therapy (PST)
Study: 16752268
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral micronized 17beta‐estradiol
Study: 8406348
Drug: Two 5‐micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 5‐micrograms doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 month (group 1)
Study: 8406348
Drug: Three 5‐micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 5‐micrograms doses of hepatitis B recombinant DNA yeast vaccine at 0, 1 and 6 months (group 2)
Study: 8406348
Drug: Three 10‐micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 10‐micrograms doses of plasma‐derived hepatitis B vaccine (group 3)
Study: 2869540
Drug: Temazepam 40
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Temazepam 40 mg orally followed by IV saline
Study: 2869540
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo followed by IV diazepam 10 mg (Diazemuls)